跳至主要内容
临床试验/NCT02922036
NCT02922036进行中(未招募)不适用

Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders, Previously Untreatable and High Risk Upgrade Patients (SOLVE CRT)

EBR Systems, Inc.127 个研究点 分布在 2 个国家目标入组 300 人开始时间: 2018年1月17日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
300
试验地点
127
主要终点
Primary Efficacy 1

研究概览

简要总结

This study is a prospective, multi-center, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.

详细描述

The WiSE-CRT System is an implantable cardiac pacing system capable of delivering pacing energy to the left ventricle of the heart without using a pacing lead.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Sequential
主要目的
Treatment
盲法
None

盲法说明

One part of the study was randomized. The final part of the study was single-arm, open label.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Primary Efficacy 1

时间窗: 6 Months

Mean relative % change in Left Ventricular End Systolic Volume (LVESV) baseline to 6 Months.

Primary Safety

时间窗: 6 Months

Freedom from Procedure and Device System related Type 1 Complications

次要结局

  • Secondary Efficacy 2(6 Months)
  • Secondary Efficacy 5(6 months)
  • Secondary Efficacy 3(6 months)
  • Secondary Efficacy 1(6 Months)
  • Secondary Efficacy 4(6 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (127)

Loading locations...

相似试验